Annual report pursuant to Section 13 and 15(d)

Licenses Acquired (Tables)

v3.19.1
Licenses Acquired (Tables)
 12 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Research and Development Arrangement, Contract to Perform for Others
For the years ended December 31, 2018 and 2017, the Company’s research and development-licenses acquired are comprised of the following:
 
 
 
For the Years Ended December 31,
 
($ in thousands)
 
2018
 
 
2017
 
Fortress
 
$
–
  
 
$
300
  
 
 
 
 
 
 
 
 
 
Partner companies:
 
 
 
 
 
 
 
 
Aevitas
 
 
1
  
 
 
–
  
Caelum
 
 
252
  
 
 
219
  
Checkpoint
 
 
1,000
  
 
 
400
  
Cellvation
 
 
1
  
 
 
–
  
Cyprium
 
 
–
  
 
 
100
  
Helocyte
 
 
1,521
  
 
 
–
  
Mustang
 
 
1,275
  
 
 
2,875
  
Tamid
 
 
–
  
 
 
270
  
Total
 
$
4,050
  
 
$
4,164
  
 
 
 
 
 
 
 
 
 
 
Schedule Of Licenses Acquired Expenses
For the years ended December 31, 2018 and 2017 Mustang recorded the following expense in research and development – licenses acquired:
 
   
For the year ended December 31,
  
($ in thousands)
  
2018
    
2017
  
City of Hope                
Manufacturing   $ 75     $ –  
IL13Rα2     –       500  
IV/ICV     –       125  
PSCA     –       300  
HER2     200       600  
CSI     –       600  
Harvard - CRISPR     –       250  
UCLA     –       200  
Fred Hutch - CD20     –       300  
St. Jude – XSCID     1,000       –  
Total   $ 1,275     $ 2,875